Hematology

There is a trend towards higher frequency of high-risk cytogenetic aberrations in patients with NRAS gene mutations compared to patients with KRAS gene mutations. Read more.

The overarching message from the symposium was that diagnosis of SM-AHN is challenging, and SM is often missed in patients with a myeloid…

The ongoing large-scale screen of non-M41 variants in patients suspected of HMs continues to detect both recurrent and novel non-M41 variants. The patients harbouring non-M41 variants are rare but may be more malignant.

A captivating session, presented at EHA Congress 2023, on sickle cell disease explored the role of allogeneic stem cell transplantation in this condition, as well as gene therapy and gene editing in treating patients with SCD.

Targeted Therapeutics in CLL and MCL. Applying Emerging BTK Inhibitor Therapy Data to Practice. This infographic was supported by educational grant from Lilly.

Patient blood management encompasses all aspects of the transfusion decision-making process, beginning with the initial patient evaluation and continuing through clinical management.

This article summarises the occurrence of very unusual and rare steroid-related toxicity. It is a cautionary tale of modern medicine where the treatment-related adverse events are more atrocious than the primary disease.

Lymphoma experts presented an insightful exploration of clinical trial data on immunotherapy and targeted therapeutics for diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.